Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Oasmia Pharmaceutical AB (publ) Stock (NASDAQ:OASM) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Get OASM alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$1.30▼$1.6252-Week Range$0.94▼$5.70VolumeN/AAverage Volume98,414 shsMarket Capitalization$3.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Read More… Coins Set to Soar with a Pro-Crypto White House (Ad)Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address OASM Stock News HeadlinesDouble Bond Pharmaceutical International AB (DBPHAb)October 31, 2024 | investing.comSector-Health Care & PharmaceuticalsMay 17, 2024 | newsweek.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 4, 2024 | Behind the Markets (Ad)BOEUF Bonesupport Holding AB (publ)April 30, 2024 | seekingalpha.comLipigon Pharmaceuticals AB LPGOMarch 23, 2024 | morningstar.comLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comResurs Holding AB (publ) (RESURS.ST)February 8, 2024 | finance.yahoo.comSee More Headlines OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oasmia Pharmaceutical AB (publ) investors own include Protalix BioTherapeutics (PLX), Amarin (AMRN), Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), VBI Vaccines (VBIV) and Verastem (VSTM). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OASM CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220,000.00 Price / Sales17.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.08Miscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$3.75 million OptionableNot Optionable Beta0.96 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:OASM) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHas World War III already started?As global tensions are rising, so does the potential of direct conflict between the US and China. That's wh...Behind the Markets | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.